<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610958</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-05-022</org_study_id>
    <nct_id>NCT03610958</nct_id>
  </id_info>
  <brief_title>Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.</brief_title>
  <official_title>Prospective, Single Center, Open-labeled Single Arm Study, to Asses the Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss in Healthy Over Weight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epitomee medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epitomee medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design to demonstrate the safety and performance of the Epitomee Device&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single center, open-labeled single arm study. The subjects will be enrolled in&#xD;
      one investigational site. Subjects meeting eligibility criteria will receive multiple capsule&#xD;
      intakes, 1 capsule twice daily for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2014</start_date>
  <completion_date type="Actual">September 4, 2018</completion_date>
  <primary_completion_date type="Actual">September 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single center, open-labeled single arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation of the Device administration.</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Normal Gastroscopic examination as assessed by an independent safety committee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change in subjects' weight presented as percent total body loss (%TBL)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Subjects loss of weight described as %TBL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Epitomee Device arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.&#xD;
The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epitomee Device</intervention_name>
    <description>A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.</description>
    <arm_group_label>Epitomee Device arm</arm_group_label>
    <other_name>Tulip Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 21 ≤ Age &lt;65 years&#xD;
&#xD;
          2. 28 &lt; BMI ≤ 40 kg/m2&#xD;
&#xD;
          3. Healthy subject&#xD;
&#xD;
          4. Normal blood count and chemistry&#xD;
&#xD;
          5. Subject is able and willing to give informed consent&#xD;
&#xD;
          6. Subject is able and willing to participate in the study and follow protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. General health and medication&#xD;
&#xD;
          1. Any history or evidence of significant cardiac, renal, neurologic, pulmonary,&#xD;
             gastrointestinal, hematologic abnormality, chronic hepatic disease or any other&#xD;
             disease or symptom which in the judgment of the investigator would interfere with the&#xD;
             study or confound the results&#xD;
&#xD;
          2. Symptomatic or unbalanced metabolic syndrome, or, symptomatic or unbalanced type 2&#xD;
             diabetes - such patients with minor symptoms may be allowed according to the PI&#xD;
             discretion&#xD;
&#xD;
          3. Intake of chronic medication which may affect the GI or interrupt with the treatment,&#xD;
             unless approved by the PI discretion&#xD;
&#xD;
          4. Taking thyroid hormone deficiency drugs (such as L-thyroxine)&#xD;
&#xD;
          5. Hemoglobin level under 11 gm/dl&#xD;
&#xD;
             B. Weight loss history and status&#xD;
&#xD;
          6. Currently using pharmaceutical agents or food supplements for weight loss&#xD;
&#xD;
          7. History of weight reduction of more than 5% of total body weight in the past 6 months&#xD;
&#xD;
          8. Eating disorder such as anorexia, bulimia compulsory overeating or emotional eating*&#xD;
&#xD;
             C. Specific GI history and status&#xD;
&#xD;
          9. History or evidence of any active liver disease. (abnormal liver functions: &gt;1.5 times&#xD;
             upper limit)&#xD;
&#xD;
         10. Subject with Inflammatory Bowel Disease (IBD)&#xD;
&#xD;
         11. Significant swallowing disorders&#xD;
&#xD;
         12. Less than 3 natural bowel movements per week&#xD;
&#xD;
         13. Past history of any gastrointestinal surgery (excluding uncomplicated appendectomy)&#xD;
&#xD;
         14. Malabsorption disorders&#xD;
&#xD;
             D. General&#xD;
&#xD;
         15. History of food allergy according to PI decision&#xD;
&#xD;
         16. Female subjects who are breastfeeding or have a positive pregnancy test at screening&#xD;
             or at any time during the study&#xD;
&#xD;
         17. History of alcohol or drug abuse within 6 months of screening&#xD;
&#xD;
         18. Mental disorders&#xD;
&#xD;
         19. Currently participating in an ongoing clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Shirin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kamila Gonczarowski Institute of Gastroenterology Assaf Harofeh Medical Center,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within six months of study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

